BioCryst Pharmaceuticals saw the highest growth of 99% in patent filings in January and 199% in grants in March in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 99% and grants by 66%. GlobalData’s DataBook provides a comprehensive analysis of BioCryst Pharmaceuticals‘s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

BioCryst Pharmaceuticals has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q1 2024

The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 8% filings and 20% grants. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), Israel(IL), and United States(US) patent Office are among the top ten patent offices where BioCryst Pharmaceuticals is filings its patents. Among the top granted patent authorities, BioCryst Pharmaceuticals has 20% of its grants in European Patent Office(EPO), 20% in Israel(IL) and 20% in United States(US).

Bayer and Vertex Pharmaceuticals could be the strongest competitors for BioCryst Pharmaceuticals

In terms of grant share, BioCryst Pharmaceuticals stands in tenth position among its competitors. Bayer and Vertex Pharmaceuticals secured the top positions according to recent patent publication data.

Patents related to rare diseases lead BioCryst Pharmaceuticals's portfolio

BioCryst Pharmaceuticals has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q1 2024.

Fibrodysplasia ossificans progressiva (myositis ossificans progressiva) related patents lead BioCryst Pharmaceuticals portfolio followed by cardiovascular disease, and acquired (autoimmune) hemolytic anemia

BioCryst Pharmaceuticals has highest number of patents in fibrodysplasia ossificans progressiva (myositis ossificans progressiva) followed by cardiovascular disease, acquired (autoimmune) hemolytic anemia, hodgkin lymphoma (b-cell hodgkin lymphoma), and chronic lymphocytic leukemia (cll).

For comprehensive analysis of BioCryst Pharmaceuticals's filings and grants, buy the databook here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.